DIOTHERIS
Diotheris develops bacterial therapies of the human skin and mucosal microbiome intended to protect against pathogenic bacteria. The company's products are based on live bacteria includes NASOFLORE which targets Staphylococcus aureus, enabling the prevention of infections due to major pathogen and protecting patients against biological threats.
DIOTHERIS
Social Links:
Industry:
Biotechnology Life Science Therapeutics
Founded:
2020-05-29
Address:
Montigny-le-bretonneux, Ile-de-France, France
Country:
France
Total Employee:
1+
Status:
Active
Total Funding:
0
Similar Organizations
Chimeron Bio
Chimeron Bio develops agents for personalized cancer gene therapy.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
MyoDOPA
MyoDOPA is develops a novel therapeutic profile providing efficient treatment.
Investors List
InnoBio Fund
InnoBio Fund investment in Seed Round - Diotheris